KR102892737B1 - 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법 - Google Patents

젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법

Info

Publication number
KR102892737B1
KR102892737B1 KR1020247025280A KR20247025280A KR102892737B1 KR 102892737 B1 KR102892737 B1 KR 102892737B1 KR 1020247025280 A KR1020247025280 A KR 1020247025280A KR 20247025280 A KR20247025280 A KR 20247025280A KR 102892737 B1 KR102892737 B1 KR 102892737B1
Authority
KR
South Korea
Prior art keywords
subject
gemcitabine
period
bladder
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247025280A
Other languages
English (en)
Korean (ko)
Other versions
KR20240119176A (ko
Inventor
데니스 기싱
크리스토퍼 큐티
Original Assignee
타리스 바이오메디컬 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타리스 바이오메디컬 엘엘씨 filed Critical 타리스 바이오메디컬 엘엘씨
Priority to KR1020257039507A priority Critical patent/KR20250174098A/ko
Publication of KR20240119176A publication Critical patent/KR20240119176A/ko
Application granted granted Critical
Publication of KR102892737B1 publication Critical patent/KR102892737B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
KR1020247025280A 2017-11-08 2018-11-07 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법 Active KR102892737B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257039507A KR20250174098A (ko) 2017-11-08 2018-11-07 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762583394P 2017-11-08 2017-11-08
US62/583,394 2017-11-08
PCT/US2018/059698 WO2019094517A1 (en) 2017-11-08 2018-11-07 Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
KR1020207016209A KR20200085822A (ko) 2017-11-08 2018-11-07 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207016209A Division KR20200085822A (ko) 2017-11-08 2018-11-07 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257039507A Division KR20250174098A (ko) 2017-11-08 2018-11-07 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법

Publications (2)

Publication Number Publication Date
KR20240119176A KR20240119176A (ko) 2024-08-06
KR102892737B1 true KR102892737B1 (ko) 2025-11-28

Family

ID=66439297

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247025280A Active KR102892737B1 (ko) 2017-11-08 2018-11-07 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
KR1020207016209A Ceased KR20200085822A (ko) 2017-11-08 2018-11-07 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
KR1020257039507A Pending KR20250174098A (ko) 2017-11-08 2018-11-07 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207016209A Ceased KR20200085822A (ko) 2017-11-08 2018-11-07 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
KR1020257039507A Pending KR20250174098A (ko) 2017-11-08 2018-11-07 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법

Country Status (18)

Country Link
US (3) US10792297B2 (https=)
EP (1) EP3706763A4 (https=)
JP (2) JP2021502347A (https=)
KR (3) KR102892737B1 (https=)
CN (1) CN111787926A (https=)
AU (1) AU2018366106B2 (https=)
BR (1) BR112020008700A2 (https=)
CA (1) CA3081839A1 (https=)
DO (1) DOP2023000155A (https=)
EA (1) EA202091143A1 (https=)
IL (2) IL302714B1 (https=)
JO (1) JOP20200124A1 (https=)
MA (1) MA50581A (https=)
MX (2) MX2020004771A (https=)
PE (1) PE20210041A1 (https=)
PH (1) PH12020550587A1 (https=)
SG (1) SG11202003950WA (https=)
WO (1) WO2019094517A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4124339T (lt) 2014-03-06 2025-11-10 Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
JOP20200124A1 (ar) * 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
WO2024092159A1 (en) * 2022-10-28 2024-05-02 Taris Biomedical Llc Methods of treating bladder cancer with gemcitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
AU2003278881A1 (en) 2002-09-23 2004-04-08 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
CA2503193A1 (en) 2002-10-22 2004-05-06 The Biomerix Corporation Method and system for intravesicular delivery of therapeutic agents
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
DK1933810T3 (da) 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
KR101538748B1 (ko) 2007-12-11 2015-07-22 메사추세츠 인스티튜트 오브 테크놀로지 이식형 의약 투여 장치와 방광과 기타 신체 낭 또는 내강의 치료 방법
CA2720523C (en) 2008-04-04 2013-12-17 Lipella Pharmaceuticals, Inc. Treatment of bladder dysfunction using liposomal botulinum toxin
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
DK2445570T3 (da) 2009-06-26 2013-02-25 Taris Biomedical Inc Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
PL3884988T3 (pl) 2009-12-17 2025-09-08 Taris Biomedical Llc Urządzenie implantowalne z tolerancją wewnątrzpęcherzową
ES2732150T3 (es) 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
WO2011153009A1 (en) 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
EP3795121A1 (en) 2010-08-05 2021-03-24 TARIS Biomedical LLC Ureteral stent drug delivery device
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
WO2012048114A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
MX365807B (es) 2010-10-27 2019-06-14 Prometic Pharma Smt Ltd Compuestos y composiciones para el tratamiento del cáncer.
WO2012079083A2 (en) 2010-12-10 2012-06-14 The Board Of Regents Of The University Of Nebraska Hemodialysis catheter with displaceable tubes to disrupt a fibrous sheath
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
EP2670398B1 (en) 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
CN104470535A (zh) 2012-03-29 2015-03-25 阿尔托生物科学有限公司 用于治疗肿瘤的方法
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
SG11201501424SA (en) 2012-08-31 2015-03-30 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
JP2016508842A (ja) 2013-03-05 2016-03-24 タリス バイオメディカル エルエルシー 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法
KR102557326B1 (ko) 2013-03-15 2023-07-19 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치
EP2968120B1 (en) 2013-03-15 2026-01-14 TARIS Biomedical LLC Drug delivery devices and methods for drug delivery
CA2944480C (en) 2013-04-10 2021-05-18 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
DE102013103986A1 (de) 2013-04-19 2014-10-23 B. Braun Avitum Ag Rezirkulationsvorrichtung eines extrakorporalen Blutbehandlungsgeräts
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
US9215250B2 (en) 2013-08-20 2015-12-15 Janus Technologies, Inc. System and method for remotely managing security and configuration of compute devices
EP3065807A1 (en) 2013-11-05 2016-09-14 TARIS Biomedical LLC Osmotic drug delivery devices, kits, and methods
LT4124339T (lt) * 2014-03-06 2025-11-10 Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu
RU2591946C2 (ru) 2014-06-24 2016-07-20 Владимир Эдуардович Анников Способ изготовления гелеобразного водосодержащего взрывчатого состава
KR20220061253A (ko) 2014-06-26 2022-05-12 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
CN118453872A (zh) 2016-05-06 2024-08-09 塔里斯生物医药公司 治疗下尿路尿道上皮癌的方法
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Also Published As

Publication number Publication date
MX2020004771A (es) 2020-10-19
IL274343B2 (en) 2023-10-01
IL302714A (en) 2023-07-01
EP3706763A1 (en) 2020-09-16
US20210085705A1 (en) 2021-03-25
US20190175637A1 (en) 2019-06-13
JP2021502347A (ja) 2021-01-28
CN111787926A (zh) 2020-10-16
MA50581A (fr) 2020-09-16
PE20210041A1 (es) 2021-01-08
JP2024009888A (ja) 2024-01-23
US12029749B2 (en) 2024-07-09
MX2023007680A (es) 2023-07-07
WO2019094517A1 (en) 2019-05-16
BR112020008700A2 (pt) 2020-10-27
US10792297B2 (en) 2020-10-06
IL274343B1 (en) 2023-06-01
PH12020550587A1 (en) 2021-04-26
CA3081839A1 (en) 2019-05-16
US20230321129A1 (en) 2023-10-12
KR20240119176A (ko) 2024-08-06
KR20250174098A (ko) 2025-12-11
SG11202003950WA (en) 2020-05-28
JOP20200124A1 (ar) 2020-05-20
DOP2023000155A (es) 2023-12-29
AU2018366106A1 (en) 2020-05-14
EP3706763A4 (en) 2021-08-11
IL302714B1 (en) 2026-01-01
IL274343A (en) 2020-06-30
AU2018366106B2 (en) 2024-11-14
KR20200085822A (ko) 2020-07-15
EA202091143A1 (ru) 2020-07-30

Similar Documents

Publication Publication Date Title
US20230321129A1 (en) Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
JP7802743B2 (ja) 薬物送達システム及びゲムシタビンによる膀胱がんの治療方法
US12059428B2 (en) Methods of treating tumor metastasis
EP3452053B1 (en) Method of treating lower tract urothelial cancer
EA045084B1 (ru) Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина
RU2799546C2 (ru) Способы лечения метастаза опухоли
HK40005970B (en) Method of treating lower tract urothelial cancer
HK40005970A (en) Method of treating lower tract urothelial cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)